caa a22 4500 465765726 CHVBK 20180323111913.0 cr unu---uuuuu 170327e19900901xx s 000 0 eng 10.1007/BF02537161 doi (NATIONALLICENCE)springer-10.1007/BF02537161 Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester [Elektronische Daten] [Tomohito Hamazaki, Eisuke Takazakura, Kenzo Osawa, Masaharu Urakaze, Saburo Yano] Eicosapentaenoic acid (EPA) ethyl ester (1.8 g/d) was administered to 16 diabetic patients (5 insulin-dependent and 11 noninsulin-dependent diabetics) for 6 mon. EPA in total plasma fatty acids increased from 4.0±2.4 mol% (mean±SD) to 7.5±3.1 mol% (p<0.001). Albumin excretion, measured with spot urine, was significantly reduced from 65 to 36 mg/g creatinine (geometric means, p<0.001). Fasting blood sugar levels, glycohemoglobin, body weight and blood pressure did not change significantly during the study. There were also no significant changes in serum levels of creatinine, urea nitrogen, total cholesterol and triglycerides. Although no overt hemorrhage was observed in the patients, hematocrit was reduced from 42.6±2.8% to 41.0±3.9% (p<0.02). Ten other similar diabetic patients (4 insulin-dependent and 6 non-insulin-dependent diabetics) were followed as a reference group, not concomitantly, for 6 mon with neither EPA ethyl ester nor placebo. The parameters mentioned above were not changed significantly in this group during 6 mon. EPA administration might retard the appearance of overt diabetic nephropathy. American Oil Chemists' Society, 1990 Hamazaki Tomohito First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-01, Toyama-shi, Toyama, Japan aut Takazakura Eisuke Department of Internal Medicine, Kurobe City Hospital, 938, Kurobe City, Toyama, Japan aut Osawa Kenzo Department of Internal Medicine, Kurobe City Hospital, 938, Kurobe City, Toyama, Japan aut Urakaze Masaharu First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-01, Toyama-shi, Toyama, Japan aut Yano Saburo First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-01, Toyama-shi, Toyama, Japan aut Lipids Springer-Verlag 25/9(1990-09-01), 541-545 0024-4201 25:9<541 1990 25 11745 https://doi.org/10.1007/BF02537161 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02537161 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hamazaki Tomohito First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-01, Toyama-shi, Toyama, Japan aut NATIONALLICENCE 700 1- Takazakura Eisuke Department of Internal Medicine, Kurobe City Hospital, 938, Kurobe City, Toyama, Japan aut NATIONALLICENCE 700 1- Osawa Kenzo Department of Internal Medicine, Kurobe City Hospital, 938, Kurobe City, Toyama, Japan aut NATIONALLICENCE 700 1- Urakaze Masaharu First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-01, Toyama-shi, Toyama, Japan aut NATIONALLICENCE 700 1- Yano Saburo First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, 930-01, Toyama-shi, Toyama, Japan aut NATIONALLICENCE 773 0- Lipids Springer-Verlag 25/9(1990-09-01), 541-545 0024-4201 25:9<541 1990 25 11745 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer